Session » Patient Perspectives Poster (PP01–PP09)

Date: Sunday, November 7, 2021

Time: 8:30AM-10:30AM

Meeting: ACR Convergence 2021

Abstract Number: PP01

Unicycling for a Cure: My UNIque Physical Activity Intervention for Rheumatoid Arthritis During the COVID19 Pandemic

Abstract Number: PP02

Leveraging Digital Health Tracking to Improve Arthritis Management

Abstract Number: PP03

Navigating Maintenance of a Rare Autoimmune Rheumatic Disease in the Context of the COVID-19 Pandemic

Abstract Number: PP04

Dual Roles: Thriving with SLE as a Medical Student

Abstract Number: PP05

Fighting Health-Related Misinformation Using Social Media / How Creating an Online Group for Patients with Relapsing Polychondritis — and Moderating It with Health Professionals — Helps Spread Reliable and Empowering Information

Abstract Number: PP06

Collaborative Advocacy Helps Me and Other Patients With Relapsing Polychondritis (“RP”’) / My life improved by helping the RP Foundation and Race for RP facilitate awareness, education, and research to improve the quality of life for patients with RP and advance a cure for this disease.

Abstract Number: PP07

How Online Spanish-Language Resources Got Me and My RA Through the COVID-19 Pandemic

Abstract Number: PP08

Should I Get the COVID-19 Vaccine With My RA? Using Evidence-Based Resources for Decision-Making

Abstract Number: PP09

Family Planning while Living with Rheumatoid Arthritis

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.